References
Martinez OM, Villanueva JC, Lawrence-Miyasaki L et al. Molecular makers of Epstein-Barr virus infection in the circulation of transplant recipients. Transplantation Proc 1995; 27: 1211–2.
Chomarat P, Briolay J, Bancherenau J, et al. Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4. Arthritis Rheum 1993; 36: 234–42.
Carini C, Margolick J, Yodoi J, Ishizaka K. Formation of IgEbinding factors by T cells of patients with human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1988; 85: 9214–18.
Depper JM, Zvaifler NJ. Epstein-Barr virus: Its relationship to the pathogenesis of rheumatoid arthritis. Arthritis Rheum 1981; 24: 755–61.
Slaughter L, Carson DA, Jensen FB, et al. In vitro effects of Epstein-Barr virus on peripheral mononuclear cells from patients with rheumatoid arthritis and normal controls. J Exp Med 1978; 14: 1429–34.
Hartung K, Le Blanc S, Franz A, et al. Schwere chronische Epstein-Barr-Virus-Infektion mit natural killer Zell Defect. Dtsch Med Wschr 1988; 113: 1960–3.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sawada, S., Mitamura, K., Takei, M. et al. Soluble CD23 levels and their correlation with erythrocyte sedimentation rate and with copy number of Epstein-Barr virus genome in rheumatoid arthritis patients. Clin Rheumatol 16, 635–636 (1997). https://doi.org/10.1007/BF02247809
Issue Date:
DOI: https://doi.org/10.1007/BF02247809